Gustavo Baldassarre

A review of the functions of human #CyclinDependentKinases, highlighting their roles in #cellcycle control, disease progression, & the therapeutic potential of #CDKInhibitors in #cancer & other diseases. @gusbald.bsky.social

#STTT: doi.org/10.1038/s413...

Great presentation at #CRO_Aviano_IRCCS by @biancastellac.bsky.social on genetic and #epigenetic alterations in #breast tissue. Thank you Biancastella, it was wonderful have you in Aviano!

This review summarizes the functions of #CyclinDependentKinases (CDKs), discusses their potential roles and deregulation in human pathologies and underscores the role of CDK inhibitors as standard therapies in #cancer. #medsky @gusbald.bsky.social @gustavo_baldassarre

#OpenAccess: buff.ly/NA2B1Fs

Sunset from #Monte_Faito #Campania #Italy. From right to left you can admire the Vesuvius Vulcan, Monte di Procida, the islands Procida, Ischia and Capri and the peninsula Sorrentina. This is the magnificent #gulf_of_Napoli

Sunrise at #Scilla #Calabria Italy! Just beautiful!!

The abstract submission for #BIG2025 are open now. | Gustavo Baldassarre The abstract submission for #BIG2025 are open now. If you are interested in presenting your work on the #surgery, #medical_therapy or #translational_research in #gynecological_cancers don't miss ...

www.linkedin.com/posts/gustav...

Just out in #Molecular_Cancer a beautiful journey with Ivana de la Serna and Francois Vallette discussing #cancer_cells #clonal_evolution and #resistance to treatments from 3 different and complementary points of view. Hope you will enjoy read this review as we enjoyed writing it.

rdcu.be/emfur

Free registration open for BIG2025.
Limited on site places. All info on: 👇
ecm.meetingsrl.eu/BIG2025/defa...

Registration for ITALIAN PARTICIPANT 👇
ecm.meetingsrl.eu/BIG2025/defa...

Registration forFOREIGN PARTICIPANT 👇
www.meetingsrl.eu/registration...

Meet the speakers
See you in Venice

Free registration open for BIG2025.
Limited on site places. All info on: 👇
ecm.meetingsrl.eu/BIG2025/defa...

Registration for ITALIAN PARTICIPANT 👇
ecm.meetingsrl.eu/BIG2025/defa...

Registration forFOREIGN PARTICIPANT 👇
www.meetingsrl.eu/registration...

Meet the speakers

Here we are!
Registration for BIG 2025 is now open. All info on: 👇
ecm.meetingsrl.eu/BIG2025/defa...

Registration for ITALIAN PARTICIPANT 👇
ecm.meetingsrl.eu/BIG2025/defa...

Registration forFOREIGN PARTICIPANT 👇
www.meetingsrl.eu/registration...

See you in Venice

Cell cycle duration determines oncogenic transformation capacity Nature - Total cell cycle duration is a key hallmark of cancer initiation, and determines whether defects in apoptosis, senescence, immune surveillance, angiogenesis, DNA repair, polarity and...

Beautiful manuscript just published in @nature.com suggesting that a shorter #cell_cycle duration is associated to a higher possibility of cell transformation. Here is the link👇🏻

rdcu.be/ek1vB

The 4th edition of BIG is approaching. An exceptional panel of speakers discussing the novelties in #translational and #clinical #gynecology_oncology. Free registration but limited places. Below, you can see the venue and meet the organizers. Stay tuned for updates. See you in #Venice

Safeguarding the future of biomedical science in the United States NIH’s abrupt decision to cap indirect cost reimbursement at 15% threatens the critical infrastructure supporting groundbreaking biomedical research in the United States. This policy jeopardizes Americ...

Safeguarding the future of biomedical science in the United States: Cell www.cell.com/cell/fulltex...

A Vaccine For Pancreatic Cancer Continues To Show Promise In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.

90% of people diagnosed with pancreatic cancer die from the disease. That's why the medical community is excited about the results of a small trial in which nearly half of the pancreatic cancer patients who received an mRNA vaccine for the disease remained relapse-free three years later.

Evolutionary fingerprints of epithelial-to-mesenchymal transition - Nature Malignant cells with mesenchymal features display increased chromatin accessibility, particularly in the pericentromeric and centromeric regions, in turn resulting in delayed mitosis and catastrophic ...

new out in @nature.com www.nature.com/articles/s41...

The 4th edition of BIG is approaching. Don’t miss the opportunity to joining us and meet an exceptional panel of speakers in the wonderful city of Venice. Stay tuned for further updates

New challenges Explore the challenges currently open for Expressions of Interest.

7 new Cancer Grand Challenges announced:

www.cancergrandchallenges.org/new-challenges
@cancergrand.bsky.social

Right now, I can't open:
www.nlm.nih.gov
ftp.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov/genbank/
pubmed.ncbi.nlm.nih.gov

As we can expect PubMed dysfunction more and more or to be swamped with fake journals I suggest you get acquainted to this nice alternative: europepmc.org

Remember, EuropePMC is actually better than #PubMed because it includes ALL preprints in search results, not just those including NIH-funded research.

europepmc.org

Enjoying skiing on Dolomiti alps in a sunny, cold Saturday with old friends! What a day!

Positano and Capri from Monte Faito, Italy

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease Signal Transduction and Targeted Therapy - Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

What a great start to 2025 having our review on the role of hashtag#CDKs in human physiology and diseases just published in #Signal_Transduction_Targeted_Therapies!
Here is the link to the open access article 👇
rdcu.be/d6a4g
A big effort of the lab but we learnt a lot!
I hope you will enjoy it

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease Signal Transduction and Targeted Therapy - Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

What a great start to 2025 having our review on the role of hashtag#CDKs in human physiology and diseases just published in #Signal_Transduction_Targeted_Therapies!
Here is the link to the open access article 👇
rdcu.be/d6a4g
A big effort of the lab but we learnt a lot!
I hope you will enjoy it

Cyclin Dependent Kinases (CDKs) are crucial for cell division and exist in 20 variations, each with unique roles. Their malfunction is linked to diseases like cancer and Alzheimer's. CDK inhibitors are now cancer treatments, and exploring their use in other diseases could help improve patient care.

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

Scientists in Italy show how cyclin-dependent kinases (CDKs) regulate cell division, gene expression, and DNA repair.

Disrupted CDKs fuel diseases like cancer, making them critical targets for therapy.

www.nature.com/articles/s41...

This paper is the result of an incredibly fun collaboration with Sandro Santagata and Peter Sorger. Led by an amazing postdoc @tanjinakader.bsky.social and JiaRen Lin, we provide a pre-cancer atlas of Fallopian tube precursors to High-Grade Serous Ovarian Cancer. The data is also on cbioportal!

Rare germline structural variants increase risk for pediatric solid tumors Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using ge...

Interesting paper now published in Science👇🏻

www.science.org/doi/10.1126/...

Schematic representation of HGSCO progression, emphasizing the temporal development of hallmark cancer features and the dynamic interplay and interactions between immune cells and precancer/cancer cells. Cancer often starts with oncogenic changes (mutations, aneuploidy, and other cancer hallmarks), under selective pressure. These cells may remain latent for decades. Only a subset of these “phenotypically normal” but mutated clones undergo clonal expansion and acquire additional mutations, ultimately developing into cancer. Early on, despite limited genomic instability, innate immune responses, including the NK-cDC1-CTL axis and tissue-resident memory T cells (TRM), help contain p53 signature cells. Increasing aneuploidy or extrinsic factors can enhance immune surveillance, potentially eliminating precancer clones before significant proliferation occurs. During early STIC expansion, there is pronounced IFN response activation, with activated cDC1 and APCs, and NK cell-secreted chemokines, further attracting cDC1. This environment suggests active immune surveillance and is accompanied by interactions among APCs, activated CD4+, and CD8+ T cells. However, immunosuppressive cells, such as M2-like macrophages and Tregs, also emerge, indicating a complex equilibrium where cytotoxic and suppressive forces coexist. As STIC lesions advance, there is a reduction in CD8+ T cells and the interactions between APCs and CD4 T cells, along with an increase in exhausted CD8+ CTL and CD4+ cells expressing LAG3, almost no NK and cDC1 cells, and more suppressive APCs. The transition from STIC to overt cancer involves hallmark mechanisms such as TGF-β signaling, which excludes CTLs, changes in cytokine and fibroblast profiles, and induction of EMT and migratory programs. Dotted arrows indicate the hypothetical timing of these events, suggesting a prolonged interval from p53 signature to early STIC, followed by a more rapid progression from early to late STIC.

Now online in Cancer Discovery: Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma - by Tanjina Kader, Jia-Ren Lin, Clemens Hug, Ronny Drapkin, Sandro Santagata, et al. doi.org/10.1158/2159...

Il mondo novax ha costruito una intera narrazione sull'efficacia e utilità dell'idrossiclorochina e azitromicina contro COVID-19. Ora lo studio "Principe" è stato ritirato.